## **PRELIMINARY AGENDA**

(as of August 26, 2025)

## WEDNESDAY, OCTOBER 29, 2025

09:00 – 10:15	Session 1: RNA Delivery Innovation & Platforms: Part 1
	Chair: Ernesto Guccione, USA
09:00 - 09:05	Opening Remarks
09:05 - 09:30	Nucleic Acid Therapeutic Unlabeled Reporter Assay (NATURA): A novel platform for high-throughput quantification of NATs' functional delivery and potency <b>Ernesto Guccione</b> Principal Investigator, The Guccione Lab, <b>Icahn School of Medicine at Mount Sinai</b> , USA
09:30 - 09:55	Modeling and Modulating Antitumor Immunity with RNA nanoparticles in 3D-Bioprinted Tumoroids  Ronit Satchi-Fainaro  Director, Cancer Biology Research Center, and Director, TAU Kahn 3D BioPrinting Initiative, TAU, IL
09:55 – 10:05	Start-Up Presentation DELiveri: Massive throughput screens to identify conjugates that promote cell delivery of nucleic acid therapeutics Yaniv Erlich CEO and Co-Founder, Eleven Therapeutics, IL
10:05 – 10:15	Start-Up Presentation Improved Delivery of RNAs for Extra-Hepatic Delivery Ruben Postel CSO & Scientific Founder, Sapreme Technologies, The Netherlands
10:15 - 10:35	Coffee Break, Visit the Exhibition & Poster Viewing
10:35 – 11:25	Session 2: RNA Delivery Innovation & Platforms: Part 2
	Chair: Ernesto Guccione, USA
10:35 – 10:55	Endosomal Escape Technology Enabling ASO Delivery and Therapeutic Applications François-Thomas Michaud, CEO, Feldan Therapeutics, Canada
10:55 – 11:05	Start-Up Presentation Utilizing Machine Learning to Unlock RNA Delivery Yogev Debbi Co-Founder & CEO, Mana.bio, IL
11:05 – 11:15	Abstract Selected talk
11:15 – 11:25	Abstract Selected talk

11:25 – 13:30	Session 3: RNA Splicing Mechanisms in Cancer
	Chair: Claudio Sette, Italy
11:25 – 11:50	SRSF1-regulated alternative splicing controls on oncogenic circuit in pancreatic cancer  Adrian R. Krainer  St. Giles Foundation Professor, Cold Spring Harbor Laboratory, New York, USA
11:50 – 12:15	Splicing dysregulation: Hallmark and therapeutic opportunity in cancer Claudio Sette Principal Investigator, Catholic University of the Sacred Heart, School of Medicine, Italy
12:15 – 12:40	Pseudoexon activation as a therapeutic approach  Brage Storstein Andresen  Head of Research, Brage Storstein Andresen Lab, University of Southern  Denmark
12:40 – 12:50	Start-Up Presentation Programmable multi-kilobase RNA editing with splice editors Jacob Borrajo Chief Executive Officer & Co-Founder, Amber Bio, USA
12:50 – 13:00	Start-Up Presentation A Proprietary Circular RNA Platform for the Treatment of Infectious Diseases, Cancers, Autoimmune and Other Diseases Peter D. Weinstein Chief Executive Officer/General Counsel, Emervax, Inc., USA
13:00 – 13:20	RNA splicing to upregulate the SNA1 gene in Dravet Syndrome Edward M. Kaye, CEO & Director, Stoke Therapeutics, USA
13:20 - 13:30	Abstract Selected Talk
13:30 – 14:30	Lunch Break, Visit the Exhibition & Poster Viewing
14:30 – 16:20	Session 4: Novel Therapeutic Applications of RNA Technology: Part 1
	Chair: Michal Lotem, IL
	Opening Remarks
14:35 – 15:00	Dual-function oligonucleotide strategies for immunotherapy of acute myeloid leukemia <b>Marcin Kortylewski</b> Principal Investigator, The Kortylewski Lab, <b>City of Hope</b> , USA
15:00 – 15:25	Therapeutic approaches for HNRNPH2-Related Neurodevelopmental Disorder, an ultra-rare neurogenetic disorder  Christopher Ricupero  Assistant Professor, Columbia University Irving Medical Center, USA

15:25 – 15:50	Working with patient communities to develop ASO based therapies  Yael Weiss
	Founder & CEO, <b>Mahzi Therapeutics</b> , USA
15:50 – 16:00	Start-Up Presentation
	Advancing RNA Therapeutics with RNA Engineering and Targeted Lipid
	Nanoparticles Delivery Min Wen Ku, Application Scientist, VectorBuilder, UK
16:00 – 16:10	Abstract selected talk
16:10 - 16:20	Abstract selected talk
	Coffee Break, Visit the Exhibition & Poster Viewing
17:00 – 19:00	Session 5: Novel Therapeutic Applications of RNA Technology: Part 2
	Chair: <b>Michal Lotem</b> , IL
17:00 - 17:25	Developing RNA based approaches for the treatment of Pompe Disease and
	neurodegenerative conditions  Emanuele Buratti
	Group Leader, Molecular Pathology Lab, <b>ICGEB</b> , Italy
	· · · · · · · · · · · · · · · · · · ·
17:25 – 17:35	Start-Up Presentation A transformative RNA (ASOs) based company for the treatment of pulmonary
	diseases
	Gili Hart
	CEO, <b>SpliSense</b> , IL
17:35 – 17:45	Start-Up Presentation
	Enabling Precision Medicine: From Liquid Biopsy to Antigen Discovery with Next-Gen Technologies
	Massimiliano Clamer
47:45 40:20	Chairman & Founder, Immagina Biotechnology, Italy
17:45 – 18:30	Industry Panel Discussion: Shaping the Future of RNA Therapeutics: Innovation, Investment, and Impact
	Panelists:
	Yael Gruenbaum Cohen, Partner & Head, aMoon Alpha, IL Michelle Lynn Hall, Associate Vice President, Eli Lilly and Company, USA
	Yaniv Erlich, CEO and Co-Founder, Eleven Therapeutics, IL
	Yael Weiss, Founder & CEO, Mahzi Therapeutics, USA
	Tamar Grossman, CEO, La Jolla Labs, USA
18:30 – 19:00	Poster Session

## THURSDAY, OCTOBER 30, 2025

08:30 - 11:00	Session 6: Novel Therapeutic Applications of RNA Technology: Part 3
	Chair: Ernesto Guccione, USA
08:30 - 08:35	Opening Remarks
08:35 - 09:00	Targeting noncoding elements to boost haploinsufficient gene expression <b>Igor Ulitsky</b> Principal Investigator, Ulitsky Lab, <b>Weizmann Institute of Science</b> , IL
09:00 - 09:25	Small and long non-coding RNA transforming cell fates in the brain  Anna Krichevsky  Professor of Neurology, Brigham and Women's Hospital and Harvard Medical School, USA
09:25 - 09:50	Exploiting the dark genome to target drug-tolerant cells and improve anticancer immune therapies  Eleonora Leucci  Principal Investigator - RNA Cancer Biology Lab, KU Leuven, Belgium
09:50 - 10:10	Targeted delivery of therapeutic oligonucleotides for the treatment of neuromuscular diseases  Oxana Beskrovnaya  Chief Innovation Officer, Dyne Therapeutics, USA
10:10 – 10:20	Start-Up Presentation Cell-free RNA as a Mediator of Inflammation: New Paradigms for Therapeutic Intervention James Posada Chief Executive Officer, Resolve Therapeutics, USA
10:20 – 10:30	Start-Up Presentation Bispecific siRNA to reduce Cardiometabolic Risk Michael Khan Chief Executive Officer, Argonaute RNA, UK
10:30 – 10:40	Start-Up Presentation Targeting miR-22 with an Antisense Oligonucleotide: a new RNA-based paradigm for treating obesity Riccardo Panella, Chief Scientific Officer, Resalis Therapeutics, Italy
10:40 - 10:50	Abstract selected talk
10:50 - 11:00	Abstract selected talk
11:00 – 11:20	Coffee Break, Visit the Exhibition & Poster Viewing
t	

11:20 – 13:25	Session 7: Innovations in Tumor Targeting and Cancer Immunotherapy Using RNA
	Chair: Rotem Karni, IL / USA
11:20 – 11:25	Opening Remarks
11:25 – 11:50	Rewriting the Message: RNA Splice Disruption Unmasks New Cancer Immunotherapy Targets Michal Lotem Head of The Hadassah Cancer Research Institute (HCRI), Hadassah Hebrew University Medical Center, IL
11:50 – 12:15	Aberrantly spliced cancer proteoforms: If you can't beat them, eat them!  Andrei Thomas-Tikhonenko  Director of Experimental Pathology, Children's Hospital of Philadelphia, USA
12:15 – 12:40	Targeting RNA processing to induce neoantigen in cancer cells  Rotem Karni  Principal Investigator, Hebrew University-Hadassah Medical School, IL and University of Pennsylvania, USA
12:40 – 13:05	A novel regulatory circuit required for tumor angiogenesis and cancer growth Claudia Claudia Ghigna Scientist, Institute of Molecular Genetics, Italy
13:05 – 13:15	Abstract Selected Talk
13:15 – 13:25	Abstract Selected Talk
13:25 – 14:30	Lunch Break, Visit the Exhibition & Poster Viewing
14:30 – 16:00	Session 8: RNA Regulation & Translation in Cancer Biology
	Chair: Claudio Sette, Italy
14:30 – 14:35	Opening Remarks
14:35 – 15:00	RNA-binding proteins in melanoma progression <b>Fátima Gebauer</b> President of the RNA Society and Principal Investigator, <b>Center for Genomic Regulation (CRG)</b> , Spain
15:00 – 15:25	Exploiting RNA translation control to fight cancer resistance  Caroline Robert  Head of Dermatology, Gustave Roussy Institute, France
15:25 – 15:50	Ultra-conserved poison exons in SR protein splicing regulator genes: Do these operate as tumour suppressors or protect the functions of specific cell types?  David Elliott  Principal Investigator, Newcastle University, UK
15:50 – 16:00	Abstract Selected Talk
16:00 – 16:20	Coffee Break, Visit the Exhibition & Poster Viewing

16:20 – 17:15	Session 9: RNA Regulation & Translation in Cancer Biology (cont.)
	Chair: Claudio Sette, Italy
16:20 – 16:45	Breast cancer transcriptomics at the bulk, single cell and spatial levels
	Carlos Caldas
	Honorary Consultant in Medical Oncology, <b>University of Cambridge</b> , UK
16:45 - 16:55	Start-Up Presentation
	Targeting m6A-RNA Biology in FTO-Dependent Cancers
	Amir Mor
	CSO, <b>RNAble</b> , IL
16:55 – 17:05	Abstract Selected Talk
17:05 – 17:15	Abstract Selected Talk

## FRIDAY, OCTOBER 31, 2025

09:00 - 10:40	Session 10: Computational & Al Applications in RNA Therapeutics: Part 1
	Chair: Rotem Karni, IL / USA
09:00 - 09:05	Opening Remarks
09:05 - 09:30	Al-Driven Design: Unlocking Novel Mechanisms in RNA Therapeutics <b>Tamar Grossman</b> CEO, <b>La Jolla Labs</b> , USA
09:30 - 09:55	miRNA-based logic circuits encoded on self-amplifying RNA for highly specific cancer cell classification Ron Weiss Principal Investigator, The Weiss Lab, Massachusetts Institute of Technology, USA
09:55 – 10:20	Harnessing RNA-Driven Intelligence to Revolutionize Personalized Cancer Therapy  Aron Popovtzer  Director of the Sharett Institute of Oncology, Hadassah Medical Center, IL
10:20 - 10:30	Abstract Selected Talk
10:30 - 10:40	Abstract Selected Talk
10:40 – 11:00	Coffee Break, Visit the Exhibition & Poster Viewing
11:00 – 13:30	Session 11: Computational & Al Applications in RNA Therapeutics: Part 2
	Chair: Rotem Karni, IL / USA
11:00 – 11:25	Decoding Cancer Complexity: Machine Learning and Transcriptomic Signatures  Shai Rosenberg  Head of the Computational Medicine Service, Hadassah Hebrew University  Medical Center, IL
11:25 – 11:50	Designing a new generation of RNA therapies with computational models and Al  Tamir Tuller  Head of the Laboratory of Computational Systems and Synthetic Biology,  Tel Aviv University, IL
11:50 – 12:00	Open Slot
12:00 – 12:10	Open Slot
12:10 – 12:20	Abstract Selected Talk
12:20 – 12:30	Abstract Selected Talk
12:30 – 13:30	Concluding Remarks & Symposium Closure
13:30 – 14:30	Lunch